LifeStance Health Group, Inc.

LFST

Nasdaq; healthcare; SIC 8000, Services-Health Services; CIK 0001845257

B/C

on the B/C boundary of 370 graded peers in healthcare

rank 146 of 370; percentile 39.3; sampling error 2.5 points; lower is stronger



B/C, the elk



Scoreboard

Profitability	D	percentile 64.2
Solvency	B/C	percentile 39.7
Growth and financing	B	percentile 29.6
Reliability	0.91 AUC	filers with $591M to $2.67B assets; 95% interval 0.88 to 0.94; 160 events, 2020 to 2025
Peer failure rate	1.01% a year	Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$591M to $2.67B assets	total assets $2.2B
Standard universe	inside	revenue above $1M and assets above $10M
Warnings	none triggered	not computable: distress
Inputs computable	10 of 14	
Graded from	filings received through Feb 25, 2026	243 days before the rescan; latest periodic filing 10-Q received Aug 6, 2026
Last close	$12.95	2026-10-23; market equity $4.9B; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Feb 25, 2026

Unless stated otherwise or the context otherwise requires, the terms "we," "us," "our," "our business," "LifeStance" and "our Company" and similar references refer to LifeStance Health Group, Inc. and its consolidated subsidiaries and supported practices. References to "our employees" and "our clinicians" refer collectively to employees and clinicians, respectively, of our subsidiaries and supported practices. References to "our patients" refer to the patients treated by such clinicians. Our vision is a truly healthy society where mental and physical healthcare are unified to make lives better.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 64.2						
Gross profitability	not computable	32.3%				
one or more required annual facts are missing						
Return on invested capital	1.2%	9.3%		71.2	74	2025-12-31

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Accruals ratio	(6.3%)	(6.6%)	57.1	807	2025-12-31
Gross margin stability, five years	not computable	2.8 pts			
five annual gross margins are required; found 0					
Solvency, sleeve percentile 39.7					
Twelve-month failure probability	not computable	0.07%			
latest liabilities, cash plus short-term investments, book equity, and shares are required					
Altman Z double-prime	1.70	(0.33)	30.0	752	2025-12-31
Net debt to EBITDA	0.52x	1.82x	32.4	75	2025-12-31
Interest coverage	2.07x	(4.51x)	18.8	81	2025-12-31
Current ratio	1.65x	2.94x	77.6	834	2025-12-31
Growth and financing, sleeve percentile 29.6					
Revenue growth, three-year compound	18.3%	10.1%	33.7	413	2025-12-31
Free cash flow growth, three-year compound	not computable	10.9%			
current FCF must be positive and base FCF must exceed $100,000					
Reinvestment rate	398.0%	37.1%	6.8	104	2025-12-31
Asset growth, three years	0.5%	2.1%	50.5	700	2025-12-31
Net share issuance, one year	1.4%	2.5%	27.6	636	2026-02-17

Among 370 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
141	LifeMD, Inc. (LFMDP)	37.8	B/C	late filer
142	Sunshine Biopharma Inc. (SBFM)	38.3	B/C	late filer
143	Sunshine Biopharma Inc. (SBFMW)	38.3	B/C	late filer
144	Artivion, Inc. (AORT)	38.8	B/C	
145	Lakeland Industries Inc. (LAKE)	39.0	B/C	late filer, fortress balance sheet
146	LifeStance Health Group, Inc. (LFST)	39.3	B/C	
147	UroGen Pharma Ltd. (URGN)	39.6	B/C	short runway
148	National Healthcare Corp. (NHC)	39.8	B/C	fortress balance sheet
149	Shattuck Labs, Inc. (STTK)	40.1	B/C	dilution
150	ImmunityBio, Inc. (IBRX)	40.4	B/C	short runway
151	Celldex Therapeutics, Inc. (CLDX)	40.7	B/C	short runway

What the price implies

at the 2026-10-23 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	124.7%	7.7%	91
Distance from 52-week high	(3.4%)	(31.4%)	90
EBIT to enterprise value	0.5%	(1.5%)	56
Free cash flow yield	2.2%	(1.0%)	66
Book value to price	0.30	0.28	52
Sales to price	0.29	0.30	48

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Composite equity issuance, five years	not computable	20.5%	
Relative strength against the sector, log excess return	0.60	(0.14)	91

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	pass
Operating cash flow above zero	pass
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	pass
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	$225.9M
Operating cash flow, four quarters	$217.9M
Months of runway	not finite
Days since last periodic filing	81 (10-Q received Aug 6, 2026)
Median daily dollar volume, 63 sessions	$43.5M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	operating income	us-gaap:OperatingIncomeLoss	$24.1M	2025-12-31	2026-02-25	10-K	26-071462
2	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	$12.4M	2025-12-31	2026-02-25	10-K	26-071462
3	income tax	us-gaap:IncomeTaxExpenseBenefit	$2.7M	2025-12-31	2026-02-25	10-K	26-071462
4	total debt	us-gaap:LongTermDebt	$282.8M	2025-12-31	2026-02-25	10-K	26-071462
5	book equity	us-gaap:StockholdersEquity	$1.5B	2025-12-31	2026-02-25	10-K	26-071462
6	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$248.6M	2025-12-31	2026-02-25	10-K	26-071462
7	total debt	us-gaap:LongTermDebt	$290.0M	2024-12-31	2025-02-27	10-K	25-029100
8	book equity	us-gaap:StockholdersEquity	$1.4B	2024-12-31	2026-02-25	10-K	26-071462
9	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$154.6M	2024-12-31	2026-02-25	10-K	26-071462
10	net income	us-gaap:NetIncomeLoss	$9.7M	2025-12-31	2026-02-25	10-K	26-071462
11	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$146.2M	2025-12-31	2026-02-25	10-K	26-071462
12	assets	us-gaap:Assets	$2.2B	2025-12-31	2026-02-25	10-K	26-071462
13	assets	us-gaap:Assets	$2.1B	2024-12-31	2026-02-25	10-K	26-071462
14	current assets	us-gaap:AssetsCurrent	$416.2M	2025-12-31	2026-02-25	10-K	26-071462
15	current liabilities	us-gaap:LiabilitiesCurrent	$252.0M	2025-12-31	2026-02-25	10-K	26-071462
16	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$808.6M	2025-12-31	2026-02-25	10-K	26-071462
17	liabilities	us-gaap:Liabilities	$682.9M	2025-12-31	2026-02-25	10-K	26-071462
18	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$41.6M	2025-12-31	2026-02-25	10-K	26-071462
19	interest expense	us-gaap:InterestExpense	$11.7M	2025-12-31	2026-02-25	10-K	26-071462
20	revenue	us-gaap:Revenues	$1.4B	2025-12-31	2026-02-25	10-K	26-071462
21	revenue	us-gaap:Revenues	$1.3B	2024-12-31	2026-02-25	10-K	26-071462
22	revenue	us-gaap:Revenues	$1.1B	2023-12-31	2026-02-25	10-K	26-071462
23	revenue	us-gaap:Revenues	$859.5M	2022-12-31	2025-02-27	10-K	25-029100
24	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$36.1M	2025-12-31	2026-02-25	10-K	26-071462
25	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$107.3M	2024-12-31	2026-02-25	10-K	26-071462
26	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$21.6M	2024-12-31	2026-02-25	10-K	26-071462
27	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$16.9M	2023-12-31	2026-02-25	10-K	26-071462
28	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$40.5M	2023-12-31	2026-02-25	10-K	26-071462
29	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$52.8M	2022-12-31	2025-02-27	10-K	25-029100

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

30	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$79.3M	2022-12-31	2025-02-27	10-K	25-029100
31	current assets	us-gaap:AssetsCurrent	$312.5M	2024-12-31	2026-02-25	10-K	26-071462
32	current liabilities	us-gaap:LiabilitiesCurrent	$228.9M	2024-12-31	2026-02-25	10-K	26-071462
33	assets	us-gaap:Assets	$2.1B	2023-12-31	2025-02-27	10-K	25-029100
34	assets	us-gaap:Assets	$2.2B	2022-12-31	2024-02-28	10-K	24-022131
35	shares outstanding	dei:EntityCommonStockSharesOutstanding	389,783,210	2026-02-17	2026-02-25	10-K	26-071462
36	shares outstanding	dei:EntityCommonStockSharesOutstanding	384,550,152	2025-02-19	2025-02-27	10-K	25-029100

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.